265 related articles for article (PubMed ID: 27256466)
1. Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children.
Yu TC; Liu AP; Lun KS; Chung BH; Yung TC
Hong Kong Med J; 2016 Aug; 22(4):314-9. PubMed ID: 27256466
[TBL] [Abstract][Full Text] [Related]
2. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
3. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
4. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
Bergeman AT; Lieve KVV; Kallas D; Bos JM; Rosés I Noguer F; Denjoy I; Zorio E; Kammeraad JAE; Peltenburg PJ; Tobert K; Aiba T; Atallah J; Drago F; Batra AS; Brugada R; Borggrefe M; Clur SB; Cox MGPJ; Davis A; Dhillon S; Etheridge SP; Fischbach P; Franciosi S; Haugaa K; Horie M; Johnsrude C; Kane AM; Krause U; Kwok SY; LaPage MJ; Ohno S; Probst V; Roberts JD; Robyns T; Sacher F; Semsarian C; Skinner JR; Swan H; Tavacova T; Tisma-Dupanovic S; Tfelt-Hansen J; Yap SC; Kannankeril PJ; Leenhardt A; Till J; Sanatani S; Tanck MWT; Ackerman MJ; Wilde AAM; van der Werf C
Circulation; 2023 Dec; 148(25):2029-2037. PubMed ID: 37886885
[TBL] [Abstract][Full Text] [Related]
5. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
Roston TM; Vinocur JM; Maginot KR; Mohammed S; Salerno JC; Etheridge SP; Cohen M; Hamilton RM; Pflaumer A; Kanter RJ; Potts JE; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Kannankeril PJ; Sanatani S
Circ Arrhythm Electrophysiol; 2015 Jun; 8(3):633-42. PubMed ID: 25713214
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
7. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
[TBL] [Abstract][Full Text] [Related]
8. Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.
Imberti JF; Underwood K; Mazzanti A; Priori SG
Heart Lung Circ; 2016 Aug; 25(8):777-83. PubMed ID: 26948768
[TBL] [Abstract][Full Text] [Related]
9. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
Roston TM; Cunningham TC; Sanatani S
Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
[TBL] [Abstract][Full Text] [Related]
10. [Clinical challenges in the management of catecholaminergic polymorphic ventricular tachycardia in children].
Ge HY; Li XM; Jiang H; Zhang Y; Liu HJ; Zheng XC; Li MT
Zhonghua Er Ke Za Zhi; 2017 Dec; 55(12):926-931. PubMed ID: 29262473
[No Abstract] [Full Text] [Related]
11. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Pflaumer A; Davis AM
Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
[TBL] [Abstract][Full Text] [Related]
12. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
Heiner JD; Bullard-Berent JH; Inbar S
Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
[TBL] [Abstract][Full Text] [Related]
13. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
[TBL] [Abstract][Full Text] [Related]
14. Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia.
Celiker A; Erdoğan I; Karagöz T; Ozer S
Cardiol Young; 2009 Feb; 19(1):45-52. PubMed ID: 19102802
[TBL] [Abstract][Full Text] [Related]
15. Catecholaminergic polymorphic ventricular tachycardia detected by an implantable loop recorder in a child.
Ergül Y; Kıplapınar N; Akdeniz C; Tuzcu V
Turk Kardiyol Dern Ars; 2013 Jul; 41(5):436-9. PubMed ID: 23917010
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
[TBL] [Abstract][Full Text] [Related]
17. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
[TBL] [Abstract][Full Text] [Related]
18. BASIC AND CLINICAL INSIGHTS IN CATECHOLAMINERGIC (FAMILIAL) POLYMORPHIC VENTRICULAR TACHYCARDIA.
Márquez MF; Totomoch-Serra A; Rueda A; Avelino-Cruz JE; Gallegos-Cortez A
Rev Invest Clin; 2019; 71(4):226-236. PubMed ID: 31448784
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
Hayashi M; Denjoy I; Extramiana F; Maltret A; Buisson NR; Lupoglazoff JM; Klug D; Hayashi M; Takatsuki S; Villain E; Kamblock J; Messali A; Guicheney P; Lunardi J; Leenhardt A
Circulation; 2009 May; 119(18):2426-34. PubMed ID: 19398665
[TBL] [Abstract][Full Text] [Related]
20. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation.
De Ferrari GM; Dusi V; Spazzolini C; Bos JM; Abrams DJ; Berul CI; Crotti L; Davis AM; Eldar M; Kharlap M; Khoury A; Krahn AD; Leenhardt A; Moir CR; Odero A; Olde Nordkamp L; Paul T; Rosés I Noguer F; Shkolnikova M; Till J; Wilde AA; Ackerman MJ; Schwartz PJ
Circulation; 2015 Jun; 131(25):2185-93. PubMed ID: 26019152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]